Cardiopolymers,

CardioPolymers is a private, venture capital backed firm which has developed a novel biopolymer approach to treating heart failure. The lead product, Algisyl-LVR, (which FDA has classified as a device), has been tested extensively and validated over the past three years The first generation product consists of a proprietary biopolymer that is implanted into strategic locations of the myocardium of the dilated left ventricle, where it subsists as a long-term implant. Providing stress relief to the myocardium by re-shaping the left ventricle and thickening the ventricle wall, the biopolymer implants produce impressive physical and physiologic changes in LV function. In 2009, the Company began a clinical evaluation at the German Heart Center in Munich for the surgical treatment of patients with dilated cardiomyopathy who require a mitral valve repair or a bypass procedure.